Premium
EBV infection of B‐CLL cells in vitro potentiates their allostimulatory capacity if accompanied by acquisition of the activated phenotype
Author(s) -
AvilaCarino Javier,
Lewin gnit,
Yamamoto Katsuhiko,
Tomita Yoshihiko,
Mellstedt Håkan,
Brodin Bertha,
Rosen Anders,
Klein Eva
Publication year - 1994
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910580511
Subject(s) - lymphoblast , biology , epstein–barr virus , immortalised cell line , phenotype , in vitro , cell culture , t cell , immunology , virus , cell , b cell , microbiology and biotechnology , genetics , immune system , antibody , gene
Epstein‐Barr virus (EBV)‐carrying immortalized lymphoblastoid cell lines (LCLs) stimulate autologous T lymphocytes in vitro. This T‐cell response is independent of the EBV‐specific cellular memory because it also occurs in experiments with cells of seronegative individuals. The question can be posed whether the T‐cell‐stimulatory potential of the LCL is coupled to its immortalized state. B‐CLL cells were exploited to study this question because the majority of clones, represented by different patients, can be infected with EBV but they rarely become immortalized. We have investigated the phenotypic changes and the T‐cell‐stimulatory capacity of EBV‐infected B‐CLL cells. One aliquot of CLL cells was infected with EBV, another was activated with a mixture of Staphylococcus aureus (SAC), IL‐2 and the supernatant from the T‐cell hybridoma MP6 (activation mixture, AcMx) and the third aliquot received both treatments. In accordance with the individual features of the clonal populations represented by each patient, the immunophenotypic changes imposed by these treatments differed. With the samples of 3 patients the allo‐stimulatory potential showed the following ranking order: EBV and AcMx‐treated cells > AcMx‐treated > EBV‐infected. An analysis of several activation‐related surface markers and adhesion molecules on the cells did not reveal any association between their expression and the EBV‐imposed potentiation of allostimulatory capacity. These results may be extrapolated to EBV‐genome‐carrying normal B cells, suggesting that they can persist in vivo only as long as they have the resting phenotype. Once they are activated, these cells may be recognized and eliminated by T lymphocytes.